Middle East & Africa Cannabis Pharmaceuticals Market Size & Outlook
Middle East & Africa cannabis pharmaceuticals market, 2018-2030 (US$M)
Related Markets
MEA cannabis pharmaceuticals market highlights
- The MEA cannabis pharmaceuticals market generated a revenue of USD 37.7 million in 2023.
- The market is expected to grow at a CAGR of 58.1% from 2024 to 2030.
- In terms of segment, epidiolex was the largest revenue generating brand type in 2023.
- Other Brands is the most lucrative brand type segment registering the fastest growth during the forecast period.
- Country-wise, Israel is expected to register the highest CAGR from 2024 to 2030.
MEA data book summary
| Market revenue in 2023 | USD 37.7 million |
| Market revenue in 2030 | USD 931.4 million |
| Growth rate | 58.1% (CAGR from 2023 to 2030) |
| Largest segment | Epidiolex |
| Fastest growing segment | Other Brands |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Sativex, Epidiolex, Other Brands |
| Key market players worldwide | Jazz Pharmaceuticals PLC, AbbVie Inc, Insys Therapeutics, Bausch Health Companies Inc |
Other key industry trends
- In terms of revenue, MEA region accounted for 1.1% of the global cannabis pharmaceuticals market in 2023.
- Globally, Latin America is projected to lead the regional market in terms of revenue in 2030.
- Latin America is the fastest growing regional market and is projected to reach USD 33,621.0 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cannabis Pharmaceuticals Market Scope
Cannabis Pharmaceuticals Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Middle East & Africa cannabis pharmaceuticals market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cannabis pharmaceuticals market will help companies and investors design strategic landscapes.
Epidiolex was the largest segment with a revenue share of 53.32% in 2023. Horizon Databook has segmented the Middle East & Africa cannabis pharmaceuticals market based on sativex, epidiolex, other brands covering the revenue growth of each sub-segment from 2018 to 2030.
Cannabis-based products and drug regulations are stringent in the MEA. The production, distribution, and consumption of any form of cannabis, including CBD, is considered illegal in this region.
The penalty for possession or consumption can be as severe as the death penalty in some Middle Eastern countries. For instance, possession of CBD oil in Saudi Arabia is considered an offense and an act of drug trafficking, accounting for the death penalty.
Reasons to subscribe to Middle East & Africa cannabis pharmaceuticals market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Middle East & Africa cannabis pharmaceuticals market databook
-
Our clientele includes a mix of cannabis pharmaceuticals market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa cannabis pharmaceuticals market , including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa cannabis pharmaceuticals market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
MEA cannabis pharmaceuticals market size, by country, 2018-2030 (US$M)
Middle East & Africa Cannabis Pharmaceuticals Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
